Tylosin is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Tylosin directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Tylosin remains protective as scientific knowledge develops.
Route-specific PDE values for Tylosin reflect systemic bioavailability differences between oral, parenteral, and inhalation administration. The parenteral PDE equals the oral PDE divided by oral bioavailability, since systemic exposure from an IV-contaminated product bypasses first-pass hepatic metabolism and gut-wall elimination.